Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03192722 · ClinicalTrials.gov registry record · NA

Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2

A NA study of Ocular Conditions Resulting in Visual Impairment, sponsored by Nova Southeastern University.

Completed
Registry status
NA
Development phase
42
Enrollment target
1
Study location

NCT03192722: Completed NA study of Ocular Conditions Resulting in Visual Impairment, sponsored by Nova Southeastern University.

NCT03192722 is a NA study of Ocular Conditions Resulting in Visual Impairment that has completed, run by Nova Southeastern University. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03192722, a NA study of Ocular Conditions Resulting in Visual Impairment, has completed, sponsored by Nova Southeastern University.

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

The effect of tinted filters and illumination on the visual performance of patients with low vision (i.e., individuals with reduced vision that is uncorrectable with glasses, surgery or treatments) has been a topic of research and discussion for many years, yet there is no current consensus or practice standard for the evaluation and recommendation of colored filters and/or illumination intensity. Anecdotally, there have been many subjective reports of improvement in visual function and comfort with the use of tinted lenses. Previous studies have attempted to elucidate the subjective improvements observed using vision tests, such as visual acuity and contrast sensitivity, and the findings have been inconsistent. Traditionally, filters and optimal illumination are prescribed clinically through a trial and error method, which involves trying various filters and lamps haphazardly to determine which if any are preferred by the patient. The investigators are proposing to evaluate whether the illumination and filters chosen in office by participants using a new assessment tool the LuxIQ/2 translate to overall patient comfort and improved speed, accuracy and print size while reading, and to evaluate whether participants have the same illumination and colored filter preference determined by the LuxIQ/2 in a clinical office setting and in their home environment. The investigators will evaluate whether participants prefer lighting determined by the new assessment tool the LuxIQ/2 in comparison to lighting determined by the OttLite Cobra in office.

Primary Outcome

Measurement based on time taking to complete reading sections

Interventions

  • DEVICE Colored near reading glasses
  • DEVICE Lighting as determined by LuxIQ/2 or OttLite Cobra

Study Locations (1)

Florida

  • Nova Southeastern University - Fort Lauderdale

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2017-04-20
Est. Completion 2023-05-31
Phase NA
Nova Southeastern University

71 total trials

What the finished NCT03192722 record still lists

NCT03192722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Ocular Conditions Resulting in Visual Impairment appearing as the primary indexed condition, and to 2 interventions - of which Colored near reading glasses is the first listed.

NCT03192722 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03192722 about?

NCT03192722 is a clinical study titled "Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2". The effect of tinted filters and illumination on the visual performance of patients with low vision (i.e., individuals with reduced vision that is uncorrectable with glasses, surgery or treatments) has been a topic of research and discussion for many years, yet there is no current consensus or pract...

What is the current status of trial NCT03192722?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2017-04-20. Estimated completion is 2023-05-31.

What conditions does trial NCT03192722 study?

This clinical trial studies the following conditions: Ocular Conditions Resulting in Visual Impairment.

What interventions are being tested in trial NCT03192722?

The interventions under investigation include: Colored near reading glasses (DEVICE), Lighting as determined by LuxIQ/2 or OttLite Cobra (DEVICE).

Who is sponsoring clinical trial NCT03192722?

This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03192722 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03192722's enrollment target sits among peer trials

42 1436th of 2000 higher than 555 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03192722, the US trial registry maintained by the National Library of Medicine. NCT03192722 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.